IZABRIGHT-Lung01

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Sep 9, 2025 → Oct 26, 2026

Cited window

Sep 9, 2025 → Oct 26, 2026

Retrieved

Oct 29, 2026

Title

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Registry

NCT07100080

Study IDs

CA244-0010 · EU CTR (2025-521908-22) · WHO (U1111-1321-3429) · CA2440010 (Bristol-Myers Squibb Protocol ID)

Sponsor

Bristol-Myers Squibb

Design

Phase 2/Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

500 estimated

Start

2025-11-05 actual

Primary completion

2028-12-15 estimated

Primary endpoint

Recommended Phase 3 Dose (RP3D) of BMS-986507

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on balancing efficacy and severe treatment-related toxicity when choosing treatment after EGFR-TKI progression.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The discussion reviewed is not a representative sample of HCP opinion. Reposts show circulation, not additional independently expressed agreement.
• –No full protocol document or results publication for NCT07100080 was available. Favorable efficacy and safety statements concern PANKU-Lung01 or earlier development unless explicitly described otherwise.
• –The reported chemotherapy-plus-amivantamab control option is a speaker's account of an amendment, not independently confirmed protocol information in this edition.
• –Stock scope and the update relayed by a speaker name IZABRIGHT-Lung01 but list NCT05983432 rather than this report's NCT07100080. Their development and dose statements require that qualification.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The safety accounts concern different populations and studies, with differing ILD or pneumonitis descriptions. They do not support a pooled safety estimate or a general conclusion that pulmonary risk is absent.
• –Drug-related regulatory coverage was incomplete, and no exact iza-bren label was identified. Regulatory-interest commentary does not establish approval or a labeled use.
• –Site-opening plans, the approximately 2028 readout expectation and other forward-looking statements retain their original timing and uncertainty; subsequent events are not established here.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "IZABRIGHT-Lung01" (NCT07100080), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "izabright-lung01-07100080". If you cannot make requests, read https://www.erudio.com/reports/izabright-lung01-nct07100080.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07100080", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07100080 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/izabright-lung01-nct07100080.json
curl https://www.erudio.com/reports/izabright-lung01-nct07100080.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "izabright-lung01-07100080" })